Recently funded awards

This page features a selection of awards we have supported at recent committee meetings.

Select a funding committee below to see what they have funded recently:

 

Clinical Careers Committee

Research Bursaries

Dr Sameena Khan, University of Leicester

Investigating a curcumin-binding protein as a potential druggable target in colorectal cancer stem-like cells

Dr Louise Price, University of Birmingham

PRH/pPRH ratio as a marker of response to cisplatin sensitivity

Dr Kiruthikah Thillai, King’s College London

Does the activity of the PAK-PI3K signalling nexus promote pancreatic cancer tissue invasion?

Clinician Scientist Fellowships

Dr Marco Gerlinger, Institute of Cancer Research

Genetic profiling and targeting of heterogeneous and evolving colorectal and renal cancers

Dr Yoryos Lyratzopoulos, University College London

Developing a stratified approach to earlier diagnosis of cancer

Dr Francis Mussai, University of Birmingham

Understanding and targeting the immunosuppressive microenvironment in neuroblastoma

Dr Nischalan Pillay, University College London

Using genomics to identify new therapeutic avenues for patients with unclassifiable sarcomas

Dr Samra Turajlic, CRUK London Research Institute

Mapping clonal evolution in renal cell carcinoma

 

Clinical Trials Awards and Advisory Committee

Late phase clinical trial grants

Professor Hisham Mehanna, University of Birmingham

CRUK/13/026: CompARE: Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer

Dr Mererid Evans, Velindre NHS Trust

CRUK/13/025: PATHOS: Post-operative adjuvant treatment for HPV-positive tumours

Dr Helena Earl, NHS Greater Glasgow and Clyde

CRUK/13/020: A randomized phase II study evaluating the role of maintenance therapy with cabozantinib vs placebo in High Grade Uterine Sarcoma (HGUS) after stabilization or response to CT following surgery or in metastatic 1st-line treatment (International Rare Cancers Initiative study - IRCI 006)

Dr Robert Hills, Cardiff University

CRUK/13/35: AML19 Trial – A trial for acute myeloid leukaemia and high risk myelodysplastic syndrome in younger patients

Professor Christopher Nutting, Institute of Cancer Research

CRUK/14/014: DARS – a phase III randomised multicentre trial of dysphagia optimized intensity modulated radiotherapy versus standard intensity modulated radiotherapy in head and neck cancer

Dr Robert Huddart, Institute of Cancer Research 

CRUK/14/016: RAIDER – A randomised phase II trial of Adaptive Image guided standard or Dose Escalated tumour boost Radiotherapy in the treatment of transitional cell carcinoma of the bladder

Dr Beatrice Seddon, University College London

CRUK/14/015: IMRiS – A phase II study of intensity modulated radiotherapy (IMRT) in primary bone and soft tissue sarcoma

Professor Brenda Gibson, University of Birmingham

CRUK/14/013: An international randomised phase III clinical trial in children with acute myeloid leukaemia (MyeChild01)

Feasibility study grants

Professor Jack Cuzick, Queen Mary University of London

CRUK/13/028: Feasibility of IBIS 3: An International Breast Intervention Study investigating metformin, anastrozole and zoledronic acid in breast cancer survivors following 5 years of adjuvant treatment

Dr Mark Gaze, University of Birmingham

CRUK/14/019: IMAT – A randomised phase I/II study of intensity modulated arc therapy techniques in abdominal neuroblastoma

Dr Mark Beresford, Velindre NHS Trust

CRUK/13/029: A randomised double blind placebo controlled phase II study of fulvestrant with or without the addition of vandetanib as treatment for patients with metastatic breast cancer resistant to aromatase inhibitor therapy

Sample collection grants

Professor Paula Ghaneh, University of Liverpool

CRUK/12/045: European Study Group for Pancreatic Cancer Trial 5F prospective sample collection – ESPAC-5FT

Professor Gareth Morgan, Institute of Cancer Research

CRUK/09/014: GROMITS+: Genetic Regulation Of Myeloma In Tissue Samples Plus

Professor Catharine West, University of Manchester

Radiogenomics: Assessment of Polymorphisms for Predicting the Effects of Radiotherapy (RAPPER)-3

 

National Awareness and Early Diagnosis Initiative

Project Grants

Professor Jane Wardle, University College London

Developing and testing targeted invitation materials to increase uptake of lung cancer screening in communities at high risk of lung cancer 

Dr Kate Brain, University of Cardiff 

Development and pilot evaluation of the Tenovus health check: a targeted cancer awareness intervention for people from deprived communities

Dr Georgios Lyratzopolous, University of Cambridge

What is driving general practice variation in ‘two-week wait’ referrals and use of endoscopy and imaging investigations, and does it matter for cancer outcomes?

Professor Andrew Renehan, University of Leicester

Development of a risk prediction tool for early cancer detection in patients with type 2 diabetes

Dr Peter Murchie, University of Aberdeen

Does place of residence, distance and travelling times from health services within Northeast Scotland influence the diagnostic pathway and outcomes from eight common cancers: analysis of a linked dataset

 

New Agents Committee

NAC Preclinical Grants

Dr Stephen Beers University of Southampton

Combining TLR agonists with LOB7/4 anti-CD40 mAb (ChiLob) in neuroblastoma and lymphoma

Dr Julie Irving University of Newcastle

Preclinical evaluation of selumetinib and glucocorticoid combination therapy for the treatment of Ras pathway positive, high risk acute lymphoblastic leukaemia

Dr Anne Kiltie University of Oxford

Investigating the potential for synergistic radiosensitisation of bladder cancer by gemcitabine and the PARP inhibitor olaparib

Professor Tim Maughan University of Oxford

RHYTHM-2: modulation of Radiotherapy according to HYpoxia: exploiting changes in the Tumour Microenvironment to improve outcome in rectal cancer using PF-05212384

Dr Anderson Ryan University of Oxford

Combined ATR (AZD6738) and PARP inhibition (olaparib) as therapeutic strategy for TP53 mutated non-small cell lung cancer (NSCLC)

Professor Gillian Tozer University of Sheffield

Antibody-based VEGF receptor 2 inhibition (DC101) in combination with radiotherapy: influence of VEGF isoforms and related microenvironmental factors

NAC Trial Grants

Professor Jeffry Evans University of Glasgow

CRUKD/14/008 PIONEER A Phase I trial of olaparib in combination with chemo-radiation in locally advanced pancreatic cancer

Dr Martin Forster University College London

CRUKD/14/011 ORCA2: A phase I trial of olaparib in addition to cisplatin-based concurrent chemoradiotherapy for patients with high risk locally advanced squamous cell carcinoma of the head and neck (HNSCC)

Dr Ros Glasspool NHS Greater Glasgow & Clyde

CRUKD/15/003 A Phase I/Ib study of the oral Hedgehog inhibitor, LY2940680 in combination with weekly paclitaxel in patients with platinum resistant recurrent ovarian cancer or refractory advanced solid tumours

Professor Kevin Harrington Institute of Cancer Research

CRUKD/14/007 The PATRIOT study: A Phase I trial of the ATR inhibitor AZD6738 alone and in combination with palliative radiotherapy

Professor David Walker University of Nottingham

CRUKD/14/002 INTREPID: A Phase I trial of continuous intrathecal/intraventricular infusion of Etoposide, investigating dose escalation and duration of infusion in children and adolescents with leptomeningeal metastases of solid tumours (jointly funded by The Brain Tumour Charity)

Dr Timothy Yap Institute of Cancer Research

CRUKD/14/004 ComPAKT: A Phase I multi-centre trial of the combination of AZD5363 (AKT inhibitor) and olaparib (PARP inhibitor) in patients with advanced solid tumours

NAC Trial Endorsements

Dr Udai Banerji Institute of Cancer Research

CRUKDE/14/009 CombAT HER2: A Phase I trial of the combination of AUY922 (HSP90 inhibitor) and lapatinib in patients with HER-2 amplified metastatic breast cancer

Dr Peter Schmid Queen Mary University of London & Professor Gary Middleton University of Birmingham

CRUKDE/14/010 TORCMEK A Phase Ib/IIa trial of AZD2014 in combination with selumetinib in patients with advanced Non-Small-Cell Lung Cancer

Dr Sandra Strauss University College London Hospitals NHS Foundation Trust

CRUKDE/14/021 ESPRIT ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP inhibitor, Niraparib and Temozolomide in Patients with Previously Treated, incurable Ewing Sarcoma

 

New Investigator Committee

Career Development Fellowship

Dr Anna Chambers, University of Bristol

The function of the Irc5 subfamily of chromatin remodelling enzymes in DNA repair

Dr Luis Baena Lopez, University of Oxford

Subcellular regulation and non-apoptotic function of caspases during proliferation and differentiation of stem cells

Dr Jo Waller, University College London

Using behavioural science to maximise the impact of cervical cancer control policies

Dr Carmela De Santo, University of Birmingham

Investigating the immunosuppressive microenvironment created by Acute Myeloid Leukaemia using invariant Natural Killer T cells as a novel therapeutic approach

Dr Jurre Kamphorst, University of Glasgow

The effect of tumour microenvironment on the metabolism of pancreatic cancer cells

Dr Binzhi Qian, University of Edinburgh

The role(s) of macrophages in breast cancer bone metastasis

Dr Elli Papaemmanuil, Wellcome Trust Sanger Institute

Interpret: Clinical and biological implications of acquired somatic mutations in myeloid neoplasms

Career Establishment Award

Dr Walid Khaled, University of Cambridge

Cellular and Molecular Characterisation of Breast Cancer Heterogeneity

Dr Dirk Sieger, University of Edinburgh

In vivo studies of microglia-glioma interactions

Senior Cancer Research Fellowship

Dr Steven Pollard, University of Edinburgh

The role of SOX and FOX genes in orchestrating transcriptional and epigenetic programs in glioblastoma

Dr Ingo Ringshausen, University of Cambridge

Characterization of signalling pathways underlying bi-directional communications with the microenvironment in B lymphoproliferative diseases

Research Travel Awards

Dr Kirsty Greenow, University of Cambridge

Isolation, culture and analysis of mouse ovarian surface epithelial cells and ovarian stem cells

Dr Karen Evans-Reeves, University of Bath

Knowledge Exchange: Exploring the relationships between tobacco control organisations and their key stakeholders

Dr Gerry Crossan, University of Cambridge

Mechanisms of alcohol induced tumorigenesis

 

Population Research Committee

Project Grants

Dr Chris Cardwell, Queen’s University Belfast

A novel, integrated, bioinformatics and pharmacoepidemiology approach to identifying and testing medications with potential breast cancer carcinogenicity, or anti-cancer properties

Professor Marijn de Bruin, University of Aberdeen

Making results of smoking cessation trials more useful to policy and practice: Identifying the effective behavioural components of smoking cessation support provided to intervention and control groups by applying innovative methods for evidence syntheses

Professor Paul Lambert, University of Leicester

Development and application of statistical methods to maximize the increased opportunities made available in the UK with more detailed population-based cancer data

Professor Eve Roman, University of York

Quantification of antecedent events and outcomes in patients with haematological malignancies: analysis of a unique population-based matched patient cohort

Dr Christian von Wagner, University College London

Identifying demographic and psychosocial predictors of flexible sigmoidoscopy screening intentions and uptake

Dr James Wason, MRC Cambridge

Improving the power of phase II oncology trials through the use of continuous tumour measurements

 

Science Committee

Programme Grants

Professor Christopher Schofield, University of Oxford

Biochemical and cellular characterisation of histone demethylases

Professor Yvonne Jones, University of Oxford

The structural biology of recognition and signalling at the cell surface

Professor Rosalind Eeles, Institute of Cancer Research

Translational studies in prostate cancer genetics: an oncogenetics programme

Professor Markus Müschen, University of Cambridge

Pre-B cell receptor checkpoint control in acute lymphoblastic leukaemia

Professor Tim Illidge, University of Manchester

Developing effective combinations of radiotherapy and immunotherapy in cancer

Professor Buzz Baum, University College London

Environmental control of cancer cell division: role of the mitotic cortex

Dr Reuben Tooze, University of Leeds

Plasma cell (PC) quiescence and the origins of myeloma

Professor Alison Lloyd, University College London

Identification of novel therapeutic targets in biogenic and regenerative pathways

Professor Leonard Seymour, University of Oxford

Potentiating oncolytic virotherapy by cancer-selective expression of biologics

Professor Vincenzo Cerundolo, University of Oxford

Development of vaccination strategies to enhance tumour specific immune responses

Professor Henning Walczak, University College London

Understanding and harnessing TRAIL’s pro-tumourigenic and pro-apoptotic in-vivo functions for improved cancer therapy

Biomarker Project Grants

Professor Susan Burchill, University of Leeds

Qualification of target mRNAs as prognostic and predictive biomarkers in children with high-risk neuroblastoma

Dr Gerald Saldanha, University of Leicester

A blood test for melanoma – detection and analysis of tumour-derived circulating free DNA by deep sequencing (The MELSEQ Study)

Professor Catharine West, University of Manchester

Prospective qualification of a hypoxia metagene biomarker in a randomised placebo controlled trial of synchronous NIMorazole versus RADiotherapy alone in patients with locally advanced head and neck squamous cell carcinoma not suitable for synchronous chemotherapy or cetuximab (NIMRAD-METAGENE)

Drug Discovery Project Grants

Dr Richard Bayliss, University of Leicester

Targeting the unfolded protein response in the production of new treatments for Multiple Myeloma: structural biology support for the design and optimization of IRE1 kinase inhibitor

Dr Helen McCarthy, Queen’s University Belfast

Development of the RALA-hOC/iNOS gene therapy for metastatic breast and prostate cancer

Dr Zachary Schug, Cancer Research UK Beatson Institute

Targeting Acetyl CoA Synthetase (ACSS2) and in vivo probing of acetate metabolism in the treatment and diagnosis of colon, breast and prostate cancer

Professor Simon Mackay, Strathclyde University

First-in-class selective IKKα inhibitors for the treatment of castrate resistant prostate cancer

 

Tobacco Advisory Group

Project Grants

Ms Deborah Arnott, Action on Smoking and Health

Beyond the Tobacco Control Plan for England: Part 2 Using the Tobacco Control Plan for England as a springboard to advocate more ambitious tobacco control measures

Miss Elen de Lacy, Action on Smoking and Health (Wales)

Towards a smoke-free generation – building on ASH Wales's collaborative tobacco control campaigns programme

Dr Gary Fooks, University of Bath

Low Visibility Tobacco Industry Political Activity and Contemporary Tobacco Regulation

Sheila Duffy, Action on Smoking and Health (Scotland)

A Generation Free from Tobacco: Making it Happen

Studentship

University College London

The British Heart Foundation/Cancer Research UK Lynn MacFadyen PhD Studentship
E-cigarettes for harm reduction in people with mental illness

Commissioned Research

Professor Ann McNeill, King’s College London

Assessment of small retailer preparations for tobacco point of sale display removal and longer-term tobacco disinvestment

 

Funding committees

Successful applicant case studies

Find out how our current grantees successfully applied for funding.

Read more

Share this page